BACKGROUND: Current organ allocation policy and the rapid growth of mechanical support favor heart transplant (HT) candidates on left ventricular assist devices. HT candidates with hypertrophic cardiomyopathy (HCM) are usually not left ventricular assist device candidates and may have a disadvantage compared with dilated forms of cardiomyopathy.
H
ypertrophic cardiomyopathy (HCM) is the most common form of inherited cardiomyopathy, present in >1:500 individuals. 1, 2 The clinical presentation and natural history of patients with HCM is diverse, ranging from an asymptomatic state to endstage heart failure and sudden cardiac death. 3 Nonobstructive forms of HCM are of particular importance as this phenotype is linked to high risk of adverse outcomes, and available therapeutic options are limited. Patients with mid and apical HCM (mainly those with small left ventricular volumes) have been shown to have an increased incidence of death and lethal arrhythmias, disabling symptoms, reduced quality of life, and progression to end-stage heart failure. 4, 5 Heart transplantation (HT) is a therapeutic option for HCM patients in a burn-out end-stage phase, characterized by progressive left ventricular dysfunction and restrictive ventricular filling. 6 Single-center studies including a limited number of patients have shown a favorable survival after HT in patients with HCM. [7] [8] [9] These findings have been supported by an analysis of the United Network for Organ Sharing (UNOS) registry conducted before the advent and exponential increase of the second and third generations of left ventricular assist devices (LVADs) as a bridge-to-transplant. 10 However, these data have been challenged by a report from large HCM referral centers suggesting an excess mortality in HCM patients early after HT, a complication attributed to a persistently elevated pulmonary vascular resistance. 6 Restoration of adequate hemodynamics by LVADs has improved HT candidate profile and survival on the transplant waitlist. [11] [12] [13] As a result, approximately half of the patients awaiting HT are supported by these devices and the impact on organ allocation has been significant. [14] [15] [16] [17] Nonetheless, HCM patients are usually not considered suitable candidates for durable LVAD support because of anatomic considerations (small ventricular cavity), with only limited data suggesting that LVAD therapy may be feasible in some HCM patients. 18 Therefore, we conducted a study to evaluate outcomes before and after HT in patients with HCM in the United States. To specifically evaluate the effect of LVAD on such outcomes, we evaluated the era effect, with a cut point selected based on the approval date of the first continuous-flow LVAD for the bridge-to-transplant indication.
METHODS
The data and analytic methods that support the findings of this study are available from the corresponding author on reasonable request.
Scientific Registry of Transplant Recipients
We used data from the Scientific Registry of Transplant Recipients (SRTR). SRTR includes data on waitlisted candidates, transplant recipients, and donors. This registry continuously receives data from centers of the Organ Procurement and Transplantation Network in the United States. The Health Resources and Service Administration and the US Department of Health and Human Services provide monitoring for the activities of Organ Procurement and Transplantation Network and SRTR. 19 Standardized policies are implemented to reduce human error in collecting data such as edit checks, validation of data at the time of entry, and interval verification when there are outliers.
Patient Population and UNOS Status
We included all adult candidates (aged ≥18 years) registered in the SRTR database for primary HT from January 19, 1999 , to October 1, 2016. Patients were grouped by their primary
WHAT IS NEW?
• The number of patients with hypertrophic cardiomyopathy (HCM) with end-stage heart failure in need of heart transplantation continues to increase. Although the use of left ventricular assist devices has reduced overall waitlist mortality, survival in HCM has minimally changed. Further, HCM candidates seem to have a greater decline in functional status compared with other patients.
• The rates of heart transplants in HCM are comparable to that of other types of cardiomyopathy. However, use of status upgrade by exception is frequent and has experienced a 2-to 4-fold increase in the current era. Finally, post-transplant survival in patients with HCM is favorable and similar to that of other forms of cardiomyopathy.
WHAT ARE THE CLINICAL IMPLICATIONS?
• As the landscape of HCM patients continues to evolve and the number of end-stage HCM patients increases, transplant programs will need to focus on interventions aimed at improving the care of such patients. This is particularly important given the potential for functional decline of these patients on the waitlist and a mortality risk that has minimally changed since the introduction of left ventricular assist devices.
• There is an unmet need to streamline the process by which HCM patients can have access to a timely transplant. Policymakers will need to monitor carefully outcomes of HCM patients in the upcoming organ allocation system and if needed develop approaches to better align their mortality risk and access to transplant. • Post-transplant survival is affected by donor and recipient factors, but not by the type of cardiomyopathy, including HCM. 
Clinical End Points and Variable Definitions
The clinical end points of interest included (1) waitlist mortality or delisting because of worsening clinical status and (2) posttransplant mortality. These outcomes were compared between groups, where patients with NICM were used as the reference group. To assess the impact of LVAD therapy implementation on these outcomes, analysis by eras was conducted.
Variables present at the time of candidate registration to the waitlist included in our analysis were age, sex, body mass index, ABO blood type, ethnicity, waitlist status, functional status, dialysis, cerebrovascular disease, previous malignancy, inotrope support, ventilator support, use of extracorporeal membrane oxygenator, VAD support, creatinine, estimated glomerular filtration rate, albumin, mean pulmonary artery pressure, pulmonary capillary wedge pressure, and cardiac output. Estimated glomerular filtration rate was calculated by using the Modification of Diet in Renal Disease Formula. 20 Functional status was classified according to the International Classification of Functioning, Disability, and Health in 3 categories: daily living assistance with total, some, and no assistance. 21 Activities of daily living included getting out of bed or a chair, dressing, eating, walking around the home, showering, or using the toilet. Decline in functional status was defined as an increase in need for assistance with activities of daily living by at least 1 grade (eg, from none to some assistance or from some to total assistance) at the time of transplant compared with the time of listing. Waitlist status is a code assigned by the Organ Procurement Organization to an HT candidate on the basis of medical urgency. Waitlist status includes 1A for candidates with the highest priority, 1B for candidates with intermediate priority, 2 for candidates with the lowest priority, and 7 for inactive patients.
Statistical Analysis
Baseline characteristics at the time of listing and at the time of HT were stratified by type of cardiomyopathy. Summary statistics were reported for quantitative variables as medians (interquartile ranges) and compared by using Kruskal-Wallis test. Qualitative variables were reported as percentages and compared by using the Pearson χ 2 test. Pairwise comparisons were performed using Rodger method. Cumulative survival rates were estimated by Kaplan-Meier survival analysis and compared between groups by means of the log-rank test. Cumulative incidence curves were constructed to illustrate the different outcomes on the waitlist (death, delisting, transplant, recovery, and ongoing listing) stratified according to the type of cardiomyopathy and by era. For the clinical end point of waitlist mortality or delisting because of worsening clinical status, time to event was the amount of time spent in the listing status until the patient was transplanted, delisted because of worsening clinical status, experienced recovery, or died. Death within 2 weeks of removal (resulting from any reason) from the waitlist, identified within Social Security Index data, was considered waitlist mortality and was included in the primary outcome. For the end point of 12-month waitlist mortality or delisting, patients without an outcome were censored at 12 months after registration. For the end point of post-transplant survival, time to event was the amount of time from transplantation to death. For this end point, survival was censored at 1 and 5 years after HT or at the end of the study period (October 1, 2016). The association of the different risk factors with the hazard of both clinical end points was assessed separately by use of univariable Cox regression analysis. The proportional hazard assumption of the Cox Regression model was assessed graphically with log-log curves and was found to be adequately met. A multivariable Cox proportional hazard model was used to determine the independent association of multiple risk factors with the hazard of evaluated end points. Variables significant at the P<0.10 level in an unadjusted analysis were considered for inclusion in the final model. Hazard ratios (HRs) and 95% confidence intervals (CIs) were generated for both univariable and multivariate analyses as measures of strength of association and precision. No substantial collinearity was detected between the tested variables. Overall, missing values for variables included in our regression analyses were <10%, except for functional status in patients with ICM, which had ≈20% missing values. All analyses were performed using Stata version 14.0 (StataCorp LLC, Lakeway Drive, TX).
RESULTS
There were 49 760 adult candidates registered for single organ primary HT in the United States during the study period. In total, 47 925 met the inclusion criteria and constituted our study group. Of these, 24 427 were registered in era 1 and 23 498 were registered in era 2. Candidates with restrictive cardiomyopathy, congenital heart disease, listing for multiple organ transplants, or redo HT (n=1835) were excluded from the analysis.
Baseline Characteristics
Among HT candidates registered in era 1 (n=24 427), 391 (1.6%) patients had HCM, 12 285 (50.3%) ICM, and 11 751 (48.1%) NICM. At the time of registration, patients with HCM were more likely to be young, of female sex, with lower burden of comorbidities, and to be listed as status 2 with longer waiting times. Although the overall use of mechanical circulatory support was less frequent in era 1, LVADs were less commonly used in patients with HCM (1.2%) compared with other types of cardiomyopathy (5.1% ICM and 4.5% NICM; P<0.01 for both comparisons; Table 1 ). Of note, the proportion of cerebrovascular events in patients with HCM (4.1%) was significant and comparable to that of patients with other types of cardiomyopathy despite their younger age and lower burden of comorbidities. In era 2, the overall number of candidate registrations remained comparable to those in era 1 (n=23 498). Compared with era 1, in era 2, there was an increase in the number of candidates registered with HCM 535 (2.3%; P=0.04) and NICM 13 605 (57.9%; P=0.03). Registrations of patients with ICM 9358 (39.8%) declined in era 2 compared with era 1 (P=0.0001). The differences in baseline characteristics between patients with HCM and other types of cardiomyopathy observed in era 2 were similar to those observed in era 1 (Table 1) .
Transplant Waitlist Outcomes
Waitlist outcomes differed in patients with HCM compared with other types of cardiomyopathy ( Figure 1 ) and by era. In era 1, the 12-month rate of HT was higher in patients with HCM (69.9%) compared with patients with ICM (57.4%) and NICM (61.5%; P<0.01; Figure 1A ). Twelve-month mortality in patients with HCM was 3.8% lower compared with patients with ICM (11.7% versus 15.5%; P=0.04) and 2.5% lower than for NICM patients (11.7% versus 14.2%; P=0.03). The rates of recovery were 1.0% lower in patients with HCM in relation to patients with ICM (0.5% versus 1.5%; P=0.02) and 1.1% lower compared with NICM patients (0.5% versus 1.6%; P=0.01). In era 2, outcomes were more comparable between the groups, including the rates of HT ( Figure 1B ). There was a significant decrease in waitlist mortality from era 1 to era 2 among patients with ICM (15.5%-8.7%; ∆: 6.8%; P=0.004) and NICM (14.2%-8.2%; ∆: 6.0%; P=0.01). However, such marked decrease in mortality was not seen in patients with HCM (11.7%-9.6%; ∆: 2.1%; P=0.06).
To better characterize the listing status urgency profile in patients with HCM at HT, we evaluated the proportion of patients whose status on the waitlist was upgraded by means of an exception criteria, that is, request of the treating team to the regional review board for a listing urgency upgrade out of the scope of the standardized urgency criteria. In era 1, status upgrade by exception was overall used infrequently (<4%). In this era, patients with HCM were 2× more likely to receive a status upgrade to 1A by exception compared with ICM (odds ratio [ 
HCM and Waitlist Outcomes
To evaluate the association of type of cardiomyopathy and more specifically of HCM with the risk of death or delisting while awaiting HT, we conducted univariable and multivariable regression analyses in both eras (Tables I and II in the Data Supplement). Many patientrelated factors, including age, comorbidities, functional status, hemodynamic parameters, renal function, and use of circulatory support, were associated with an increased risk for this outcome. However, candidates with HCM were not at increased risk of death or delisting compared with patients with NICM (era 1: HR, 0.97; 95% CI, 0.75-1.25 and era 2: HR, 0.96; 95% CI, 0.76-1.22) and ICM (era 1: HR, 0.81; 95% CI, 0.62-1.04 and era 2: HR, 0.79; 95% CI, 0.63-1.07) on univariable analysis in either era. These findings were confirmed after adjustment for potential confounders on multivariable analysis (Table II in the Data Supplement) . Of note, the use of LVAD was associated with 68% lower risk of waitlist death or delisting in the most recent era (Table II in 
Factors Associated With Waitlist Death or Delisting in Patients With HCM
To gain further insight into the potential risk factors associated with increased waitlist mortality in patients with HCM, we performed exploratory analysis for each type of cardiomyopathy separately. Most traditional risk factors were included in the univariable analysis for waitlist mortality in patients with HCM, ICM, and NICM (Tables III through V in the Data Supplement). The use of LVAD was associated with lower risk of death or delisting in patients with ICM and NICM, but not in patients with HCM (Table III through V in the Data Supplement). We performed a multivariable analysis for each type of cardiomyopathy and an overall model by era (Table 2; Table V in the Data Supplement). Among patients with HCM, independent predictors of waitlist death or delisting because of worsening clinical status included male sex, initial listing status (UNOS 1A), functional status (total assistance), need for dialysis, elevated mean pulmonary artery, and pulmonary capillary wedge pressures. Importantly, known predictors of survival such as age, body mass index, diabetes mellitus, cerebrovascular disease, and LVAD support were not significantly associated with waitlist death or delisting in HCM patients on univariable analysis of either era and thus were not included in the multivariable models specific to HCM. Conversely, LVAD support was associated with lower risk of waitlist death or delisting in patients with ICM (HR, 0.52; 95% CI, 0.32-0.83) and NICM (HR, 0.47; 95% CI, 0.34-0.66) in era 2, the most relevant era for mechanical circulatory support. At 12 months of listing in era 1 (A), patients with hypertrophic cardiomyopathy (HCM) were transplanted more frequently (69.9% vs 57.4% vs 61.5%; P=0.01), had similar mortality (11.7% vs 15.5% vs 14.2%; P=0.07) and lower incidence of recovery (0.5% vs 1.5% vs 1.6%; P=0.02) compared with ischemic cardiomyopathy (ICM) and non-ICM (NICM) patients, respectively. In era 2 (B), patients with HCM had similar rates of heart transplant (HT) 12 months after listing (64.8% vs 60.9% and 62.7%; P=0.06) and lower incidence of recovery (0% vs 1.0% vs 1.8%; P=0.04) compared with ICM and NICM patients, respectively. In relation to era 1, there was a significant decrease in 12-month mortality in era 2 among patients with ICM (15.5%-8.7%; ∆: 6.8%; P=0.004) and NICM (14.2%-8.2%; ∆: 6.0%; P=0.014). Decrease in 12-month mortality for patients with HCM in era 2 was minimal (11.7%-9.6%; ∆: 2.1%; P=0.06).
HCM and Post-Transplant Survival
Among 31 473 patients who underwent HT, 661 patients had HCM, 14 102 ICM, and 16 710 NICM. Patients with HCM were younger and had a lower prevalence of diabetes mellitus compared with ICM and NICM patients (Table VI in the Data Supplement). In era 1, the proportion of patients who required total assistance to perform activities of daily living at the time of transplant compared with the time of listing decreased in patients with ICM (10.3% versus 11.6%; P=0.04) and NICM (12.9% versus 13.6%; P=0.06), whereas it increased in patients with HCM (15.6% versus 11.0%; P=0.02). In era 2, there was a decline in the proportion of patients who required total assistance to perform activities of daily living at the time of transplant compared with the time of listing in patients with ICM (28.7% versus 39.9%; P<0.01) and NICM (29.7% versus 42.5%; P<0.01), whereas it remained steady for patients with HCM (36.8% versus 35.5%; P=0.32; Table VII in the Data Supplement). Further, a decline in functional status (increase in level of assistance needed of at least 1 grade from listing to time of transplant) occurred in 23% of patients with NICM, 23% with ICM, and 33% with HCM (P<0.0001 for both comparisons with HCM).
In patients with HCM, 1-year survival after HT was higher compared with ICM patients (91.6% versus 87.5%; P=0.03) and similar to that for NICM patients (91.6 versus 91.3%; P=0.71; Figure 3A) . Such differences in survival were more pronounced 5 years after HT (Figure 3B) , when survival for patients with HCM was higher than for patients with ICM (82.5% versus 75.3%; P=0.01) and NICM (82.5% versus 77.2%; P=0.04). A similar pattern was observed when patients were stratified by decade ( Figure IA 
DISCUSSION
The present study evaluated outcomes in patients with end-stage HCM while on the waitlist and after HT in an era marked by the growing use of mechanical circulatory support. The main finding of our study is that waitlist mortality for patients with HCM is substantial and comparable to that of candidates with ICM and NICM. Although broader regional sharing of cardiac allografts and greater use of LVADs as bridge-to-transplantation have resulted in lower overall waitlist mortality, patients with HCM have not benefited to the same extent from these strategies. 12, 15, 22 The Organ Procurement and Transplantation Network has recently approved a major change to the adult heart allocation system in the United States. 23, 24 In the new 7-tier allocation system, patients with the diagnosis of HCM will be listed in the fourth priority tier, unless further support is required with devices such as an extracorporeal membrane oxygenator, acute percutaneous, or more durable surgically implanted circulatory support devices (Table X in the Data Supplement). Several concerns in the HCM field exist with the newly approved allocation system. As longevity in HCM has increased with approaches directed at reduction of sudden cardiac death, the number of patients with HCM who progress to the end-stage phase of the disease and may benefit from HT is no longer negligible (44% increase in waitlist registrations in era 2). 3, 6, 25 The fact that most patients with HCM are not candidates for mechanical circulatory support has been perceived as a disadvantage in access to transplantation in the current allocation system, which favors candidates supported by temporary and durable mechanical circulatory support. Hence, many requests for higher urgency status by exception are currently submitted and approved through the established UNOS process-the number of transplants in HCM patients in listing status upgrades done by exception, outside the standard criteria, has nearly tripled in the Values are reported as n (%) for qualitative variables and median (interquartile range) for quantitative variables. ADL indicates activities of daily living; BMI, body mass index; CVD, cerebrovascular disease; ECMO, extracorporeal membrane oxygenator; eGFR, estimated glomerular filtration rate; HCM, hypertrophic cardiomyopathy; IABP, intra-aortic balloon pump; ICM, ischemic cardiomyopathy; LVAD, left ventricular assistance device; NICM, nonischemic cardiomyopathy; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RVAD, right ventricular assistance device; TAH, total artificial heart; and VAD, ventricular assist device.
* contemporary era. Although the allocation changes set to go into effect in 2018 seem to provide more advantage to patient groups not eligible for mechanical circulatory support such as HCM, restrictive cardiomyopathy, and congenital heart disease, presence of mechanical circulatory support will continue to be an important clinical determinant of transplant urgency. It will therefore be important to carefully assess whether these changes will result in appropriate alignment of the waitlist mortality risk in HCM patients and access to timely transplant, given the lack of satisfactory options for durable mechanical circulatory support.
Beyond mortality, quality of life and functional capacity are also important considerations in HCM patients. Our data show that functional status decline occurs in 33% of patients with HCM compared with 23% of patients with NICM and 23% of ICM (P<0.0001 for both comparisons). Thirty-seven percent of patients with HCM will require total assistance at the time of transplant. Such impairment in functional capacity was associated with higher waitlist and post-transplant ADL indicates activities of daily living; BMI, body mass index; CI, confidence interval; CVD, cerebrovascular disease; ECMO, extracorporeal membrane oxygenator; eGFR, estimated glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HR, hazard ratio; IABP, intra-aortic balloon pump; ICM, ischemic cardiomyopathy; LVAD, left ventricular assistance device; NICM, nonischemic cardiomyopathy; PAP, pulmonary artery pressure; and PCWP, pulmonary capillary wedge pressure.
*Values not included in the multivariate model. Testing for type of cardiomyopathy by era (interaction term) in a total cohort (all subgroups combined) model (not shown) was statistically significant at a joint P value of 0.02. mortality in our study, a factor that could compromise outcomes in HCM patients if waiting times for transplantation continue to increase. Further, the functional status of patients with HCM could be adversely affected by the higher than expected prevalence of cerebrovascular events observed in our study. This finding could be related to rates of atrial fibrillation in patients with HCM (20%) that are higher than for the general population (3%). 26, 27 In regards to post-transplant survival in HCM patients, there have been previous reports of increased mortality early after HT. 6, 10 Our study confirms that these findings in patients transplanted in a more distant era, where we found a trend toward higher 1-year mortality in HCM patients compared with NICM patients before 2010. However, this early hazard was no longer seen in the current decade ( Figure 3) . Further, contrary to some other reports, long-term post-transplant survival is not inferior in HCM patients. 8, 10 In fact, our study shows that adjusted 5-year survival in HCM patients was similar to that of patients with ICM and NICM. This suggests that comorbidities and other factors, 28, 29 but not the type of cardiomyopathy, have greater impact on post-transplant survival.
Study Limitations
The main strength of the present study is its specific analysis of all patients listed for HT in the United States with complete recognition of vital status and a detailed analysis by era and type. However, we recognize that there are limitations related to the retrospective nature of our study. The validity of the information is dependent on the accuracy of data entry. Although the SRTR data set is assessed by edit checks, validation of data at the time of entry, and internal verification when there are outliers, there could be a degree of inaccuracy in terms of the primary diagnosis (ie, HCM) and difficulties in the classification of patients when multiple diagnoses are suspected. Missing data are an important limitation, in particular for the analysis of patient functional status (19% missing values) . Evaluation of the association of candidate functional status and outcomes must be expanded in future studies using a more detailed approach. There were several differences in baseline characteristics between the study groups that could have influenced our results. Although multivariable analyses were conducted to account for such differences, numeric variation between the groups could have limited our analyses. More refined clinical characterization of the patients with HCM (eg, apical HCM, burned-out HCM, recurrent ventricular tachycardia, etc.) was not possible in our analysis.
Conclusions
The number of patients with HCM who develop advanced heart failure requiring evaluation for HT continues to increase. Waitlist mortality of HCM patients remains substantial and with minimal decline after the introduction of the newer generation of LVADs. Furthermore, patients with HCM seem to have a decline in functional status by the time of HT. An increasing number of listing status upgrades by exception are being submitted in HCM patients, who have limited mechanical circulatory support options. Whether the 2018 change in the UNOS heart allocation system will better align the risk of waitlist mortality in HCM patients with access to timely transplant, without the need for allocation rule exceptions, should be carefully examined. In the meantime, investigation aimed at better clinical characterization of patients with HCM may be beneficial to improve the performance of the current and future organ allocation systems. Finally, long-term survival in HCM patients has improved over time and is now similar or better compared with patients transplanted for NICM and ICM cardiomyopathy.
